Components:
Treatment option:
Medically reviewed by Militian Inessa Mesropovna, PharmD. Last updated on 25.03.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
Лидент Бэби (Lidocaine Hydrochloride,Cetylpyridinium chloride) TEETHING GEL is indicated for use in teething. Лидент Бэби (Lidocaine Hydrochloride,Cetylpyridinium chloride) TEETHING GEL acts quickly to help relieve teething pain and soothe toddlers' and infants' gums. It also has mild antiseptic properties.
Лидент Бэби (Lidocaine Hydrochloride,Cetylpyridinium chloride) TEETHING GEL is suitable for babies from the age of 3 months.
A small quantity of Лидент Бэби (Lidocaine Hydrochloride,Cetylpyridinium chloride) TEETHING GEL, approximately one third of an inch (7.5 mm, 0.22g), should be squeezed onto the tip of a clean finger and rubbed gently onto the affected area of the gum.
Application may be repeated after an interval of 20 minutes if necessary, with up to six applications in one day.
Hypersensitivity to lidocaine hydrochloride and/or cetylpyridinium chloride or to any of the excipients listed in section 6.1.
The recommended dose should not be exceeded. Keep out of the sight and reach of children.
Patients with rare hereditary problems of fructose intolerance should not use this medicine.
Лидент Бэби (Lidocaine Hydrochloride,Cetylpyridinium chloride) Teething Gel has no influence on the ability to drive and use machines.
When used according to instructions side effects would not be expected. However, isolated cases of hypersensitivity to lidocaine hydrochloride have been reported in adults and in a child over 12 years following local injection. Hypersensitivity presented in these cases as localised oedema with slight difficulty in breathing or as generalised rash.
Chamomile, a minor ingredient in the herbal flavouring agent, has been documented as causing allergic reactions. Hypersensitivity to chamomile normally manifests as breathing difficulties in atopic individuals. Anaphylactic reactions have been reported in individuals drinking herbal tea infusions containing chamomile (herbal tea asthma). Sensitised individuals may demonstrate positive skin reactions to preparations containing chamomile.
In the event of any unwanted side effects, use should be discontinued and a doctor consulted.
Post-marketing Data:
Adverse drug reactions (ADRs) identified during post-marketing experience with Cetylpyridinium/Lidocaine are included in Table 1. The frequencies are provided according to the following convention:
Very common >1/10
Common >1/100 and < 1/10
Uncommon >1/1,000 and <1/100
Rare >1/10,000, and <1/1,000
Very rare <1/10,000
Not known (cannot be estimated from the available data)
| Table 1: Adverse Drug Reactions Identified During Post-Marketing Experience with Cetylpyridinium/Lidocaine Frequency Category Estimated from Clinical Trials or Epidemiology Studies | |
| SOC | |
| Frequency category | Adverse Event Preferred Term |
| Immune System Disorders | |
| Not known | Hypersensitivity (including Dermatitis) |
| General Disorders and Administration Site Conditions | |
| Not known | Application site reactions (including Erythema) |
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Cetylpyridinium
Ingestion of cetylpyridinium in large doses may cause gastric upset and central nervous system depression. Concentrations where overdose symptoms were observed were 70 times higher than the concentrations of cetylpyridinium chloride found in this product.
Lidocaine
Systemic toxic effects with local anaesthetics (all forms of administration) may include central nervous system and cardiac effects.
No symptoms of overdosage have been identified from the analysis of post-marketing data for this product.
Pharmacotherapeutic group: Anaesthetics, local (Amides) Lidocaine combinations
ATC code: N01 BB52
Established local anaesthetic (lidocaine) for topical application.
None stated.
No additional information.
None known
No special requirements for disposal
